Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.

• DOI: 10.1200/jco.2022.40.16_suppl.9006
• Publication Date: 2022-06-06T18:04:22Z
• Authors: Catherine A. Shu; Koichi Goto; Yuichiro Ohe; Benjamin Besse; Se-Hoon Lee; Yongsheng Wang; Frank Griesinger; James Chih-Hsin Yang; Enriqueta Felip; Rachel E. Sanborn; Reyes Bernabe Caro; Joshua C Curtin; Jun Chen; Janine M. Mahoney; Leonardo Trani; Joshua Michael Bauml; Roland Elmar Knob...; Meena Thayu; Byoung Chul Cho
• Keywords: Osimertinib; Regimen; Chemotherapy regimen

9006 Background: Initial results with the amivantamab (ami) and lazertinib (laz) regimen showed encouraging efficacy in patients (pts) whose disease progressed after standard-of-care osimertinib (osi) platinum-based chemotherapy (pt-chemo; Shu Ann Oncol 2021; 32:S949-1039; 1193MO). We present updated of this population (Cohort A) from CHRYSALIS-2 study (NCT04077463). Methods: Cohort A evaluated ami laz pts EGFR exon 19 deletion or L858R NSCLC on 1st/2nd-line osi followed by pt-chemo as last line therapy (target population, n=106) among a more heavily-pretreated (n=56) ± other therapies without regard to number sequence these therapies. Pts received 1050 mg IV (1400 mg, ≥80 kg) + 240 oral laz. Investigator (INV)- blinded independent central review (BICR)-assessed response per RECIST v1.1 is reported for efficacy-evaluable pts, defined who initiated treatment before 17 Mar 2021, allowing ≥6 mo follow-up durability. Results: As 6 Nov 162 were enrolled (median 62 y, 65% women, 61% Asian, median 3 [range, 2–14] prior lines). Median time between first dose was 6.3 2.0 target populations, respectively. Of 50 overall rate (ORR) BICR 36% (95% CI, 23–51), 1 complete (CR) partial responses (PRs), clinical benefit (CBR) 58% 43–72); full all will be at meeting. duration (mDOR) not reached based BICR. At 8.3 mo, 7 responders (39%) have achieved DOR lasting INV-assessed consistent 56 (8.7-mo follow-up), ORR INV 29% 17–42), CR 15 PRs. CBR 55% 42–69) mDOR 8.6 4.2–NR). are pending. Preliminary evidence CNS antitumor activity 8 baseline brain lesions (7 non-target, target) had radiation within year enrollment. Most frequent adverse events (AE) infusion-related reaction (65%), paronychia (49%), rash (41%), stomatitis (39%). common grade ≥3 treatment-related AEs (TRAEs) reactions (7%), acneiform dermatitis (5%), hypoalbuminemia (4%). TRAEs leading discontinuation either both occurred 12% 7%, Conclusions: Among an unselected that has exhausted SOC pt-chemo, demonstrates manageable safety profile. Clinical trial information: NCT04077463.